BioDelivery Sciences International (NASDAQ:BDSI) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 1.57 by 7 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold.
Other Equity analysts have also commented on the company shares. Equity analysts at the Brokerage firm Cantor Fitzgerald downgrades its rating on BioDelivery Sciences International (NASDAQ:BDSI). The rating major has initiated the coverage with hold rating on the shares. Earlier, the shares were rated a Buy by the brokerage firm. The Analysts at Cantor Fitzgerald lowers the price target from $9 per share to $5 per share. The rating by the firm was issued on May 11, 2016.
BioDelivery Sciences International (NASDAQ:BDSI) stock has received a short term price target of $ 7.43 from 7 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $4.2. The higher estimate of target price is $16 , while the lower price target estimate is $4
BioDelivery Sciences International (NASDAQ:BDSI) rose 3.39% or 0.08 points on Tuesday and made its way into the gainers of the day. After trading began at $2.36 the stock was seen hitting $2.45 as a peak level and $2.29 as the lowest level. The stock ended up at $2.44. The daily volume was measured at 916,126 shares. The 52-week high of the share price is $9.91 and the 52-week low is $1.86. The company has a market cap of $131 million.
BioDelivery Sciences International, Inc. has dropped 0.41% in the last five trading days, however, the shares have posted positive gains of 25.13% in the last 4 weeks. BioDelivery Sciences International, Inc. has dropped 15.57% during the last 3-month period . Year-to-Date the stock performance stands at -49.06%.
BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Companys products and certain of its product candidates utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Companys United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved product BUNAVAIL (buprenorphine and naloxone buccal film) and its product candidate, BELBUCA utilize its BEMA technology.